Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets - 29/02/24
Abstract |
In recent years, several monoclonal antibodies (mAbs) targeting PD-L1 have been licensed by the FDA for use in the treatment of cancer, demonstrating the effectiveness of blocking immune checkpoints, particularly the PD-1/PD-L1 pathway. Although mAb-based therapies have made great strides, they still have their limitations, and new small-molecule or PROTAC-molecule inhibitors that can block the PD-1/PD-L1 axis are desperately needed. Therefore, it is crucial to translate initial in vitro discoveries into appropriate in vivo animal models when creating PD-L1-blocking therapies. Due to their widespread availability and low experimental expenses, classical immunocompetent mice are appealing for research purposes. However, it is yet unclear whether the mouse (m) PD-L1 interaction with human (h) PD-1 in vivo would produce a functional immunological checkpoint. In this review, we summarize the in vitro and in vivo experimental studies of small molecules and PROTAC molecules, particularly the distinctions between mPD-L1 as a target and hPD-L1 as a target.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | It is yet unclear if the mPD-L1/hPD-1 interaction would produce a Functional immunological checkpoint in vivo. |
• | We outlined the most variation among mPD-L1 and hPD-L1 when used as targets. |
• | We summarized PROTACs-based molecules that inhibit cancer by targeting PD-L1. |
Keywords : Small-molecule inhibitors, PROTAC-molecule degraders, Immune checkpoints, PD-1/PD-L1 axis, Cancer
Plan
Vol 172
Article 116257- mars 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?